Haemonetics (HAE) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.04 per share a year ago. These figures are ...

Bank of America lowered shares of Haemonetics (NYSE:HAE – Free Report) from a neutral rating to an underperform rating in a research report released on Friday, MarketBeat.com reports.

Barrington analyst Michael Petusky lowered the firm’s price target on Haemonetics (HAE) to $95 from $108 and keeps an Outperform rating on the shares post the fiscal Q3 report. The firm cites ...

BofA analyst Craig Bijou downgraded Haemonetics (HAE) to Underperform from Neutral with a price target of $68, down from $95, after Q3 revenue missed and the company lowered FY25 organic growth ...

StockNews.com upgraded shares of Haemonetics (NYSE:HAE – Free Report) from a hold rating to a buy rating in a report published on Friday. HAE has been the topic of a number of other reports.

Net Leverage Ratio: Approximately 2.42 times EBITDA. Haemonetics Corp (NYSE:HAE) reported a 4% increase in third-quarter revenue on a reported basis, with adjusted earnings per share up 14%.

Ratings for Haemonetics (NYSE:HAE) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ...

Revenue: US$348.5m (up 3.7% from 3Q 2024). Net income: US$37.5m (up 20% from 3Q 2024). Profit margin: 11% (up from 9.3% in 3Q 2024). The increase in margin was driven by higher revenue. EPS: US$0.75 ...